By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax  Antibody phage display

Company News
Merrimack (MACK) Announces A Leading-Edge Biomarker-Selected, Multi-Arm Basket Trial That Matches Patients With Most Appropriate Combination Regimens 5/19/2016 9:22:18 AM
Merrimack (MACK) To Present On Extensive Oncology Pipeline At The 2016 ASCO Annual Meeting 5/19/2016 6:59:15 AM
Merrimack (MACK) And Baxalta (BXLT) Announce Initiation Of Phase 1 Study Of MM-151 In Combination With The ONIVYDE (Irinotecan Liposome Injection) Regimen In Metastatic Colorectal Cancer 5/19/2016 6:27:16 AM
Merrimack (MACK) Presents Expanded Analysis From Seribantumab (MM-121) Phase 2 Breast Cancer Study At The AACR Precision Medicine Series 5/18/2016 7:10:24 AM
Merrimack (MACK) Reports First Quarter 2016 Financial Results 5/3/2016 7:51:16 AM
Merrimack (MACK) Announces Timing Of First Quarter 2016 Investor Conference Call 4/21/2016 6:38:32 AM
Merrimack (MACK) Unveils Its Latest Antibody Directed Nanotherapeutic, MM-310, At The 2016 AACR Annual Meeting 4/21/2016 6:30:05 AM
Leica Biosystems And Merrimack (MACK) To Collaborate On Development Of A Heregulin Companion Diagnostic For Seribantumab 4/15/2016 6:13:42 AM
Merrimack (MACK) Announces Inclusion of ONIVYDE (Irinotecan Liposome Injection) As A Category 1 Treatment Option In The 2016 NCCN Guidelines For Pancreatic Adenocarcinoma 3/24/2016 12:27:30 PM
Merrimack (MACK) To Present On Multiple Oncology Programs At The 2016 AACR Annual Meeting 3/17/2016 7:26:55 AM